BMRN - BioMarin Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
103.58
+0.85 (+0.83%)
As of 11:48AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close102.73
Open102.26
Bid103.36 x 800
Ask103.43 x 1000
Day's Range102.26 - 103.74
52 Week Range75.81 - 104.00
Volume214,301
Avg. Volume1,353,306
Market Cap18.304B
Beta2.04
PE Ratio (TTM)N/A
EPS (TTM)-0.84
Earnings DateAug 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est114.67
Trade prices are not sourced from all markets
  • PR Newswire6 days ago

    BioMarin to Host Second Quarter 2018 Financial Results Conference Call and Webcast on Thursday, August 2 at 4:30pm ET

    SAN RAFAEL, Calif. , July 11, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a ...

  • Barrons.com8 days ago

    Gene Therapy: BioMarin, Spark Can Both Win Treating Hemophilia

    Gene therapy has been hailed as a potential breakthrough treatment for many diseases, and today Credit Suisse's Martin Auster takes a look at its future for hemophilia treatment. Auster writes that gene therapy could become a "foundational approach in hemophilia management," with important data points due out this summer from Spark Therapeutics (ONCE) Pfizer (PFE) that will "incrementally evolve the landscape." He writes that there are signs of high patient demand for new treatments, and that gene therapy could be a more cost-efficient way to improve poor outcomes for hemophilia patients in the emerging markets. The stakes are still high: Auster believes that if issues arise, "uptake would ultimately disappoint greatly," but if long-term safety and durability is established, he expects "broad adoption of gene therapy given convenience and economic benefits." Ultimately, he believes that in this environment, the binary debate of Spark versus BioMarin Pharmaceuticals (BMRN) isn't the full picture.

  • PR Newswire8 days ago

    BioMarin Partners with Believe Limited for 'Breaking Through!' Musical Theater Intensive

    SAN RAFAEL, Calif., July 9, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) today announced an exclusive partnership with Believe Limited to produce the 'Breaking Through!' musical theater intensive. The first-of-its-kind program is a three-day music workshop for the bleeding disorders community and is designed to provide young adults with powerful education on the healing and therapeutic power of the arts and self-expression. The musical workshop, directed by hemophilia advocate and Believe Limited CEO Patrick James Lynch, will be held from November 9 – November 12, 2018 and will culminate in a Broadway-style performance for local bleeding disorder community members, family and friends.

  • Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns
    Zacks12 days ago

    Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns

    Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.

  • Rare disease drug maker BioMarin's unusual path to campus expansion in Marin: Team up with a local senior center
    American City Business Journals14 days ago

    Rare disease drug maker BioMarin's unusual path to campus expansion in Marin: Team up with a local senior center

    The rare-disease drug developer and San Rafael nonprofit Whistlestop have set their sights on securing the building approvals necessary to redevelop 999 Third St. into two massive research facilities and a building with an active aging center topped with senior affordable housing.

  • ACCESSWIRE15 days ago

    Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Arena Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / July 2, 2018 / Major U.S. markets finished higher on Friday, but finished the week lower due to ongoing global trade concerns. The Dow Jones Industrial Average increased 0.23 ...

  • See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
    Markit17 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 13. Index (PMI) data, output in the Healthcare sector is rising.

  • PR Newswire19 days ago

    BioMarin Announces First Recipients of RARE Scholars Scholarship Program

    Five Students with Rare Genetic Diseases Receive a Total of $20,000 for Higher Education SAN RAFAEL, Calif. , June 28, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that ...

  • See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
    Markit19 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 13. Index (PMI) data, output in the Healthcare sector is rising.

  • GlobeNewswire20 days ago

    Report: Developing Opportunities within American Homes 4 Rent, Invitation Home, Graphic Packaging Holding, Flotek Industries, Sunstone Hotel Investors, and BioMarin Pharmaceutical — Future Expectations, Projections Moving into 2018

    NEW YORK, June 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of American ...

  • ACCESSWIRE28 days ago

    Free Technical Research on BioPharmX and Three More Biotech Equities bio

    LONDON, UK / ACCESSWIRE / June 19, 2018/ If you want a free Stock Review on BPMX sign up now at www.wallstequities.com/registration. On Monday, June 18, 2018, the Dow Jones Industrial Average and the S&P 500 edged 0.41% and 0.21% lower, respectively at the closing bell, while the NASDAQ Composite stayed bullish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), BioPharmX Corp. (NYSE AMER: BPMX), BioTime Inc. (NYSE AMER: BTX), and bluebird bio Inc. (NASDAQ: BLUE).

  • BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 8.5%
    Zacks29 days ago

    BioMarin Pharmaceutical (BMRN) Catches Eye: Stock Jumps 8.5%

    BioMarin Pharmaceutical (BMRN) shares rose nearly 9% in the last trading session, amid huge volumes.

  • ACCESSWIRE29 days ago

    Today’s Research Reports on Stocks to Watch: Geron Corporation and BioMarin Pharmaceutical

    NEW YORK, NY / ACCESSWIRE / June 18, 2018 / Biotech stocks Geron Corporation and BioMarin Pharmaceutical were both rising in Friday’s trading session with gains of almost 10% by the close of the day. While Geron had no significant news, BioMarin announced last week that it has dosed its first participant in a global phase II study for vosoritide, an experimental drug for the treatment of achondroplasia.

  • BioMarin Begins Pediatric Study on Achondroplasia Candidate
    Zackslast month

    BioMarin Begins Pediatric Study on Achondroplasia Candidate

    BioMarin Pharmaceutical (BMRN) initiates phase II study on vosoritide for the treatment of achondroplasia in infants and children up to five years of age.

  • 3 Biotech Stocks Up in the Past Month on Industry Turnaround
    InvestorPlacelast month

    3 Biotech Stocks Up in the Past Month on Industry Turnaround

    After a strong start in 2018, the drug sector struggled a bit in the next few months probably on U.S. market instability and a few negative updates on the pipeline and regulatory front. In the first four months of the year (January-April), the biotech industry significantly underperformed the S&P 500. The biotech industry declined 9.3% compared with the S&P 500’s decline of 0.8%.

  • PR Newswirelast month

    BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia

    SAN RAFAEL, Calif., June 14, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that the company dosed the first participant in a global Phase 2 study for vosoritide, an analog of C-type Natriuretic Peptide (CNP), in infants and young children with achondroplasia, the most common form of disproportionate short stature in humans. "Vosoritide represents an innovative therapy to treat the underlying cause of achondroplasia. At the molecular level, vosoritide corrects the signaling process that determines skeletal growth and proportionality of bones, while the body is still growing," said Hank Fuchs, M.D., President, Worldwide Research and Development at BioMarin.

  • See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • Why I Just Bought These 3 Stocks
    Motley Foollast month

    Why I Just Bought These 3 Stocks

    There are thousands of publicly traded stocks, but I settled on adding these three to my portfolio this month.

  • PR Newswirelast month

    BioMarin Receives Milestone Payments from Pfizer for Talazoparib

    SAN RAFAEL, Calif. , June 7, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Company received $20 million in milestone payments from Pfizer Inc.  These milestone ...

  • 3 Biotech Stocks Up in the Past Month on Industry Turnaround
    Zackslast month

    3 Biotech Stocks Up in the Past Month on Industry Turnaround

    We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.

  • Why Sesen Bio Stock Jumped Over 37% this Week
    Market Realist2 months ago

    Why Sesen Bio Stock Jumped Over 37% this Week

    Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies based on Targeted Protein Therapeutics platform for the treatment of patients with cancer. The stock jumped ~26.1% to $2.27 yesterday. The above chart shows analysts’ recommendations for Sesen Bio over the last three months. The stock price has increased ~37.6% in last three trading sessions. It has increased by ~68.8% over the last 12 months and 201.8% year-to-date. On May 30, Sesen Bio announced the pricing of the underwritten public offering of ~22.2 million shares of its common stock at $1.80 per share, the closing price on May 30.

  • Catalyst's Fridapse Gets Priority Review by FDA, Shares Up
    Zacks2 months ago

    Catalyst's Fridapse Gets Priority Review by FDA, Shares Up

    The FDA grants Priority Review to Catalyst's (CPRX) lead pipeline candidate, Firdapse, and set an action date of Nov 28, 2018.

  • 5 Biotech Stocks to Boost Your Portfolio’s Health This Year
    InvestorPlace2 months ago

    5 Biotech Stocks to Boost Your Portfolio’s Health This Year

    Also, a slowdown in sales of some of the most high-profile older drugs, courtesy of payers and competitive pressure from both branded and generic drugs, is a concern for the sector. Drug pricing has been in the spotlight once again this month when President Donald Trump announced plans to lower prescription drug costs.

  • Analysts’ Recommendations for Incyte in May
    Market Realist2 months ago

    Analysts’ Recommendations for Incyte in May

    Wall Street analysts expect the company to see a 40.9% rise in revenue to $459.8 million in Q2 2018. Incyte’s stock price has fallen nearly 51.7% over the last 12 months and nearly 29.6% in 2018 year-to-date. Wall Street analysts’ recommendations show a 12-month target price of $81.0 per share compared to its price of $66.67 per share on May 24.

  • American City Business Journals2 months ago

    Why this biotech exec broke down on a conference call over company's new rare-disease drug

    Critics targeted the company's spending over 10 years of research and development on a drug that treats a rare, brain-damaging inherited disease. It was an emotional moment last week when the drug won approval.